Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are used to treat asthma and other respiratory diseases by relaxing the muscles in the airways. The Eastern Asia region has witnessed a significant growth in the Bronchodilator Drugs market in recent years.
Customer preferences: The increasing prevalence of respiratory diseases and the rising awareness about the importance of early diagnosis and treatment have led to a surge in demand for bronchodilator drugs in Eastern Asia. Patients are increasingly opting for combination therapies that offer better symptom relief and improved quality of life.
Trends in the market: Japan, China, and South Korea are the largest markets for bronchodilator drugs in Eastern Asia. Japan has a well-established healthcare system and a high prevalence of respiratory diseases, which has led to a high demand for bronchodilator drugs. China and South Korea have witnessed a significant increase in the prevalence of respiratory diseases in recent years, which has led to a surge in demand for bronchodilator drugs.In Japan, the market is dominated by long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), which are used in combination with inhaled corticosteroids (ICS) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The market for combination therapies is expected to grow in the coming years, driven by the increasing demand for improved symptom relief and better quality of life.In China, the market is dominated by short-acting beta-agonists (SABAs) and short-acting muscarinic antagonists (SAMAs), which are used for the treatment of asthma and COPD. The market for LABAs and LAMAs is expected to grow in the coming years, driven by the increasing demand for combination therapies.In South Korea, the market is dominated by LABAs and ICS, which are used in combination for the treatment of asthma and COPD. The market for LAMAs is expected to grow in the coming years, driven by the increasing demand for combination therapies.
Local special circumstances: The Eastern Asia region has a large population and a high prevalence of respiratory diseases, which has led to a surge in demand for bronchodilator drugs. The region has a well-established healthcare system and a high level of healthcare spending, which has enabled patients to access high-quality medical care.
Underlying macroeconomic factors: The Eastern Asia region has witnessed a rapid economic growth in recent years, which has led to an increase in the disposable income of the population. This has enabled patients to access high-quality medical care and has led to a surge in demand for bronchodilator drugs. The region has a large aging population, which is more susceptible to respiratory diseases, which has further driven the demand for bronchodilator drugs. The increasing prevalence of smoking and air pollution in the region has also contributed to the surge in demand for bronchodilator drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
